Ellex gets CE mark for laser eye treatment
26 February, 2014 by Dylan Bushell-EmblingEllex Medical Lasers (ASX:ELX) has been granted approval to market 2RT - a laser therapy for chronic eye disease AMD - in the European Union.
Benitec to raise up to $31.5m in placement
25 February, 2014 by Dylan Bushell-EmblingBenitec Biopharma (ASX:BLT) has launched a private placement to raise up to $31.5 million to further its ddRNAi development programs.
AusBiotech members recognised in Healthcare Awards
25 February, 2014Admedus, Nanosonics, Universal Biosensors and CSL were among the companies recognised last week as Australia's best performers in the Australian healthcare industry at the 2014 Frost & Sullivan Australia Healthcare Awards.
Simavita commences trading on ASX
21 February, 2014 by Dylan Bushell-EmblingSimavita (ASX:SVA) has commenced trading on the ASX, as the company gears up for the US launch of its Smart Incontinence Management product.
Australia to put spotlight on global brain mapping initiatives
20 February, 2014Australia is to host an eminent world congress as the prominence of brain mapping is growing around the globe. Recent and significant initiatives from the US and Europe have been initiated to better understand the brain and develop new and better treatments for conditions like Alzheimer's, autism and depression, and to help people suffering from brain injuries.
ABCA appoints Ken Matthews as chairman
19 February, 2014 by Dylan Bushell-EmblingFormer Department of Agriculture secretary Ken Matthews has joined the Agricultural Biotechnology Council of Australia (ABCA) as chairman.
Invion teams with 3M for inhaled respiratory drugs
19 February, 2014 by Dylan Bushell-EmblingInvion (ASX:IVX) has signed a deal to develop and evaluate inhaled versions of its two respiratory drug assets using inhaler technology from 3M Drug Delivery Systems.
Boom time for Australian life sciences sector
18 February, 2014 by Dylan Bushell-EmblingDespite a flat fourth quarter, the Australian life sciences sector significantly outperformed the All Ordinaries Index in 2013, but PwC believes the challenge will be sustaining the boom.
New reports show GM crop usage, benefits and role in future food security
18 February, 2014The Australian Biotechnology Council of Australia (ABCA) has advised that two key agricultural biotechnology resources released globally last week outline the increasing global uptake of GM crops, their benefits and their role in ensuring food security in a changing climate.
Prima BioMed replaces director
13 February, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has appointed Pete Meyers, currently CFO of TetraLogic Pharmaceuticals, as a non-executive director to replace Dr Richard Hammel.
Last call for companies to assist with 2014 key surveys: metrics from CEOs, manufacturing and medtech in China
13 February, 2014Three key surveys are in their final weeks as biotech and medtech companies are urged to assist with views and metrics that underpin advocacy efforts and the development of industry resources.
AusBiotech responds to the review of employee share schemes
11 February, 2014AusBiotech has responded on behalf of its members to the federal government's review of employee share schemes (ESS) for start-ups, making both direct and written submissions to the review last week.
Cochlear 1H profit slumps 73%
11 February, 2014 by Dylan Bushell-EmblingCochlear (ASX:COH) has blamed delays receiving anticipated regulatory approval for new products and the potential costs of a patent violation lawsuit on a steep decline in 1H14 net profit.
Admedus gets FDA approval for CardioCel
10 February, 2014 by Dylan Bushell-EmblingThe US FDA has granted marketing approval for Admedus's (ASX:AHZ) CardioCel for use in cardiac repair surgeries in adults and children.
Clinuvel's Scenesse being trialled in HHD
10 February, 2014 by Dylan Bushell-EmblingAn Italian phase II trial of Clinuvel's (ASX:CUV) Scenesse in rare skin condition Hailey-Hailey Disease has commenced, with recruitment due to be complete by March.
